Plasma CAF22 and NfL reflect neuromuscular decline during cisplatin-based chemotherapy and radical cystectomy in muscle-invasive bladder cancer
International Journal of Clinical Oncology · 2025-12 · 30 (12) · 2626-2634
DOI: 10.1007/s10147-025-02890-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 27.09.2025. Verfasst von Rizwan Qaisar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical Sciences, College of Medicine, University of Sharjah, 27272, Sharjah, United Arab Emirates. rqaisar@sharjah.ac.ae. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Neurofilament Proteins, Peptide Fragments, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: University of Sharjah.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Cisplatin-based chemotherapy and radical cystectomy are standard treatments for muscle-invasive bladder cancer (MIBC), but their impact on neuromuscular integrity and functional capacity remains elusive. We investigated plasma biomarkers of neuromuscular junction degradation (c-terminal agrin-fragment-22; CAF22) and neuronal injury (Neurofilament light-chain; NfL) in relation to physical capacity in MIBC patients. METHODS: In this prospective study, 42 MIBC patients undergoing neoadjuvant cisplatin-gemcitabine chemotherapy and radical cystectomy were assessed before (T1) and after (T2) chemotherapy, and 4-6 weeks post-surgery (T3). Age- and BMI-matched controls (n = 46) were evaluated once. Plasma CAF22 and NfL were measured alongside handgrip strength (HGS), gait speed (GS), appendicular skeletal muscle index (ASMI), and short physical performance battery (SPPB). RESULTS: Plasma CAF22 and NfL were significantly elevated in patients versus controls at all time points. NfL showed more modest increases in post-treatment. HGS declined from 22.3 ± 3.9 kg at T1 to 17.2 ± 3.3 kg at T3 (p < 0.05), along with reductions in ASMI and GS. Cumulative SPPB scores dropped from 9.02 ± 1.02 to 8.24 ± 1.32. Sarcopenia prevalence rose from 28.5% at T1 to 52.4% at T3. CAF22 was significantly associated with lower HGS and SPPB at T1 (β = - 0.58 and - 0.42, p < 0.001). CAF22 changes correlated with HGS (r = - 0.80) and SPPB (r = - 0.75), while NfL showed weaker but significant correlations. Lab results indicated declines in hemoglobin, albumin, and renal function markers consistent with treatment effects. CONCLUSIONS: CAF22 showed strong associations with treatment-related decline in skeletal muscle, suggesting its potential as an early biomarker of sarcopenia that warrants validation in larger cohorts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Basic Medical Sciences, College of Medicine, University of Sharjah, 27272, Sharjah, United Arab Emirates. rqaisar@sharjah.ac.ae.
- Space Medicine Research Group, Research Institute of Medical and Health Sciences, University of Sharjah, 27272, Sharjah, United Arab Emirates. rqaisar@sharjah.ac.ae.
- Cardiovascular Research Group, Research Institute of Medical and Health Sciences, University of Sharjah, 27272, Sharjah, United Arab Emirates. rqaisar@sharjah.ac.ae.
- Medical Oncology Department, Hayatabad Medical Complex, Peshawar, 25120, Pakistan.
- Department of Basic Medical Sciences, College of Medicine, University of Sharjah, 27272, Sharjah, United Arab Emirates.
- Space Medicine Research Group, Research Institute of Medical and Health Sciences, University of Sharjah, 27272, Sharjah, United Arab Emirates.
Förderung
- University of Sharjah
Zitieren
APA
Qaisar, R., Hussain, S., Ahmad, F., & Karim, A. (2025). Plasma CAF22 and NfL reflect neuromuscular decline during cisplatin-based chemotherapy and radical cystectomy in muscle-invasive bladder cancer. International Journal of Clinical Oncology, 30(12), 2626-2634. https://doi.org/10.1007/s10147-025-02890-3
Vancouver
Qaisar R, Hussain S, Ahmad F, Karim A. Plasma CAF22 and NfL reflect neuromuscular decline during cisplatin-based chemotherapy and radical cystectomy in muscle-invasive bladder cancer. International Journal of Clinical Oncology. 2025;30(12):2626-2634. doi:10.1007/s10147-025-02890-3
BibTeX
@article{Qaisar2025,
author = {Qaisar, Rizwan and Hussain, Shah and Ahmad, Firdos and Karim, Asima},
title = {Plasma CAF22 and NfL reflect neuromuscular decline during cisplatin-based chemotherapy and radical cystectomy in muscle-invasive bladder cancer},
journal = {International Journal of Clinical Oncology},
year = {2025},
volume = {30},
number = {12},
pages = {2626--2634},
doi = {10.1007/s10147-025-02890-3}
}
EUVIMED